Trial · NCT00457015
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose | KALBITOR (Ecallantide) | MSCS Score at baseline | 2.2 | Standard Deviation 0.50 | units on a scale |
| Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose | Placebo | MSCS Score at baseline | 2.0 | Standard Deviation 0.35 | units on a scale |
| Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose | KALBITOR (Ecallantide) | MSCS Score at 4 hours post-dose | 1.4 | Standard Deviation 0.75 | units on a scale |
| Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose | Placebo | MSCS Score at 4 hours post-dose | 1.6 | Standard Deviation 0.77 | units on a scale |
| Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose | KALBITOR (Ecallantide) | Change from baseline in MSCS at 4 hours post-dose | -0.8 | Standard Deviation 0.63 | units on a scale |
| Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose | Placebo | Change from baseline in MSCS at 4 hours post-dose | -0.4 | Standard Deviation 0.82 | units on a scale |
| Treatment Outcome Score at 4 Hours Post-Dose | KALBITOR (Ecallantide) | 53.4 | Standard Deviation 49.70 | units on a scale | |
| Treatment Outcome Score at 4 Hours Post-Dose | Placebo | 8.1 | Standard Deviation 63.18 | units on a scale | |
| Patients With Significant Improvement in Overall Response | KALBITOR (Ecallantide) | 22 | participants | ||
| Patients With Significant Improvement in Overall Response | Placebo | 12 | participants | ||
| Patients With a Successful Response at 4 Hours Post-dosing, Based on the Change From Baseline in the MSCS Score | KALBITOR (Ecallantide) | 45 | participants | ||
| Patients With a Successful Response at 4 Hours Post-dosing, Based on the Change From Baseline in the MSCS Score | Placebo | 28 | participants | ||
| Proportion of Patients Maintaining a Significant Improvement in Overall Response Through 24 Hours | KALBITOR (Ecallantide) | 21 | participants | ||
| Proportion of Patients Maintaining a Significant Improvement in Overall Response Through 24 Hours | Placebo | 10 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00457015/results